An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects With Advanced Solid Tumors
Latest Information Update: 26 Dec 2022
At a glance
- Drugs GLR 2007 (Primary)
- Indications Advanced breast cancer; Brain metastases; Glioblastoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Gan&Lee Pharmaceuticals
Most Recent Events
- 21 Dec 2022 Status changed from active, no longer recruiting to completed.
- 15 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 16 Jul 2020 Status changed from not yet recruiting to recruiting.